Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), in combination with paclitaxel (taxane) or carboplatin, significantly improved the median overall survival (OS) and PFS of NSCLC patients with tumours of nonsquamous cell histology [91]. This evidence concerns the gene VEGFA and neoplasm.